Martin Kaiser
The Royal Marsden · Institute of Cancer Research, United Kingdom · University of Leeds
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Martin Kaiser as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:18 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07284758 · A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaC4 Therapeutics, Inc. · recruiting · Multiple Myeloma, Relapsed/Refractory Multiple Myeloma · principal investigator
- Ph2NCT06212596 · Selinexor, Cyclophosphamide and Prednisone in MyelomaUniversity of Leeds · completed · Relapsed or Refractory Multiple Myeloma · principal investigator
- Ph2NCT03188172 · MUK Nine b: OPTIMUM Treatment ProtocolUniversity of Leeds · unknown · Multiple Myeloma · principal investigator
- Ph2NCT02406222 · Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)University of Leeds · active not recruiting · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:18 UTC. The ranking covers the 200 most relevant of 70 PubMed records, and a shared surname and initials can bring in a namesake. All 70 on PubMed
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.J Clin Oncol · 2015472 citationsRCR 12.9
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2019309 citationsRCR 11.7
- 208 citationsRCR 7.8
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.Lancet Haematol · 2020206 citationsRCR 9.2
- 197 citationsRCR 5.9
- 143 citationsRCR 4.8
- Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.Eur J Haematol · 2006123 citationsRCR 2.8
- Using computerized games to teach face recognition skills to children with autism spectrum disorder: the Let's Face It! program.J Child Psychol Psychiatry · 2010115 citationsRCR 4.3
- Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.Diabetes Obes Metab · 2009114 citationsRCR 3.3
- A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.Lancet Haematol · 2019103 citationsRCR 4.4